238 related articles for article (PubMed ID: 17408938)
21. Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells.
Pospischil A; Walther P; Dingemanse J
Exp Toxicol Pathol; 2010 Sep; 62(5):567-71. PubMed ID: 19674876
[TBL] [Abstract][Full Text] [Related]
22. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds.
Hanumegowda UM; Wenke G; Regueiro-Ren A; Yordanova R; Corradi JP; Adams SP
Chem Res Toxicol; 2010 Apr; 23(4):749-55. PubMed ID: 20356072
[TBL] [Abstract][Full Text] [Related]
23. Influence of a pre-existing phospholipidosis on the accumulation of amiodarone and desethylamiodarone in rat alveolar macrophages.
Reasor MJ
Res Commun Chem Pathol Pharmacol; 1991 May; 72(2):169-81. PubMed ID: 1876748
[TBL] [Abstract][Full Text] [Related]
24. Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS.
Hasegawa M; Takenaka S; Kuwamura M; Yamate J; Tsuyama S
Exp Toxicol Pathol; 2007 Oct; 59(2):115-20. PubMed ID: 17719757
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis.
Hirode M; Ono A; Miyagishima T; Nagao T; Ohno Y; Urushidani T
Toxicol Appl Pharmacol; 2008 Jun; 229(3):290-9. PubMed ID: 18355885
[TBL] [Abstract][Full Text] [Related]
26. Monitoring the accumulation of fluorescently labeled phospholipids in cell cultures provides an accurate screen for drugs that induce phospholipidosis.
Nioi P; Pardo ID; Snyder RD
Drug Chem Toxicol; 2008; 31(4):515-28. PubMed ID: 18850360
[TBL] [Abstract][Full Text] [Related]
27. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays.
Mesens N; Steemans M; Hansen E; Verheyen GR; Van Goethem F; Van Gompel J
Toxicol In Vitro; 2010 Aug; 24(5):1417-25. PubMed ID: 20430096
[TBL] [Abstract][Full Text] [Related]
28. From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier.
Yang L; Zhong X; Li Q; Zhang X; Wang Y; Yang K; Zhang LW
Toxicol Sci; 2017 Mar; 156(1):39-53. PubMed ID: 28013220
[TBL] [Abstract][Full Text] [Related]
29. Lead-induced phospholipidosis and cholesterogenesis in rat tissues.
Ademuyiwa O; Agarwal R; Chandra R; Behari JR
Chem Biol Interact; 2009 May; 179(2-3):314-20. PubMed ID: 19056365
[TBL] [Abstract][Full Text] [Related]
30. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities.
Tengstrand EA; Miwa GT; Hsieh FY
Expert Opin Drug Metab Toxicol; 2010 May; 6(5):555-70. PubMed ID: 20370598
[TBL] [Abstract][Full Text] [Related]
31. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.
Ploemen JP; Kelder J; Hafmans T; van de Sandt H; van Burgsteden JA; Saleminki PJ; van Esch E
Exp Toxicol Pathol; 2004 Mar; 55(5):347-55. PubMed ID: 15088636
[TBL] [Abstract][Full Text] [Related]
32. Detection of metabolic activation leading to drug-induced phospholipidosis in rat hepatocyte spheroids.
Takagi M; Sanoh S; Santoh M; Ejiri Y; Kotake Y; Ohta S
J Toxicol Sci; 2016 Feb; 41(1):155-64. PubMed ID: 26763403
[TBL] [Abstract][Full Text] [Related]
33. Effect of drug-induced phospholipidosis on pulmonary disposition of pneumophilic drugs.
Ohmiya Y; Angevine LS; Mehendale HM
Drug Metab Dispos; 1983; 11(1):25-30. PubMed ID: 6132791
[No Abstract] [Full Text] [Related]
34. A fluorescence-based rapid screening assay for cytotoxic compounds.
Montoya J; Varela-Ramirez A; Estrada A; Martinez LE; Garza K; Aguilera RJ
Biochem Biophys Res Commun; 2004 Dec; 325(4):1517-23. PubMed ID: 15555600
[TBL] [Abstract][Full Text] [Related]
35. Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay.
Sawada H; Taniguchi K; Takami K
Toxicol In Vitro; 2006 Dec; 20(8):1506-13. PubMed ID: 16919414
[TBL] [Abstract][Full Text] [Related]
36. Amiodarone pulmonary toxicity: biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects.
Martin WJ; Standing JE
J Pharmacol Exp Ther; 1988 Feb; 244(2):774-9. PubMed ID: 3346847
[TBL] [Abstract][Full Text] [Related]
37. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis.
Joshi UM; Rao P; Kodavanti S; Lockard VG; Mehendale HM
Biochim Biophys Acta; 1989 Aug; 1004(3):309-20. PubMed ID: 2758025
[TBL] [Abstract][Full Text] [Related]
38. A live-cell fluorescence microplate assay suitable for monitoring vacuolation arising from drug or toxic agent treatment.
Coleman J; Xiang Y; Pande P; Shen D; Gatica D; Patton WF
J Biomol Screen; 2010 Apr; 15(4):398-405. PubMed ID: 20237207
[TBL] [Abstract][Full Text] [Related]
39. [Chloroquine keratopathy as an example of drug-induced phospholipidosis (contribution to the pathogenesis of cornea verticillata) (author's transl)].
Seiler KU; Thiel HJ; Wassermann O
Klin Monbl Augenheilkd; 1977 Jan; 170(1):64-73. PubMed ID: 15159
[TBL] [Abstract][Full Text] [Related]
40. Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
Natale A; Boeckmans J; Desmae T; De Boe V; De Kock J; Vanhaecke T; Rogiers V; Rodrigues RM
Toxicol Lett; 2018 Mar; 284():184-194. PubMed ID: 29248575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
